Maryam Bakhtiari Koohsorkhi
Junfeng Wu
Vahid Ziaee- 1Children's Medical Center, Pediatrics Center of Excellence, Tehran, Iran
- 2Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, China
- 3Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran
- 4Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Science, Tehran, Iran
- 5Pediatric Rheumatology Society of Iran, Tehran, Iran
Editorial on the Research Topic
Case Reports in Pediatric Rheumatology 2022
The field of pediatric rheumatology is thriving and growing in science. the body of clinical knowledge and scientific work in this area has expanded exponentially and is receiving worldwide attention. the recently discovered field of autoinflammatory diseases describes disorders that are at the crossroads of immunology and rheumatology and the joint effort is shedding new light on the unclear pathogenesis, and helping in the identification of new treatment options. Systemic autoinflammatory diseases (SAIDs) consist of multisystem immune dysregulation disorders caused by the dysfunction of the innate immune system in the absence of infections or autoimmunity (1, 2).
For nearly 3 years, the main focus of the academic world has mostly been on COVID-19, presentations, complications, and treatment strategies. however, it seems like the appropriate time to attract attention and put emphasis on case reports, unusual presentations, and new and experimental treatment options for other rheumatologic diseases. Case reports count as a great source of new ideas and information in clinical medicine and it has the ability to report original discoveries and novel treatment strategies.
The present Special Issue entitled “A Review on new Case Reports in Pediatric Rheumatology 2022” aims to explore the advances in pediatric rheumatology and case reports chosen in this research topic represent some of the fresh advances in the field.
The recent discovery of monogenic inborn errors of immunity and the so-called subgroup of autoinflammatory disorders has broadened the field of pediatric rheumatology. Early age of presentation and familial tendencies are clues to the possibility of an underlying monogenic pattern. It is already known that autoimmunities are more common in relatives of children with SLE (3). Repetitive patterns in family members of lupus patients are in favor of underlying genetic causes. Mikhail M. Kostik et al. reported a case of 2 monozygotic twin brothers with simultaneous childhood SLE. This compelling case report emphasizes the possibility of monogenic origin in childhood SLE and justifies the need to perform WGS to study the spectrum of genetic variants associated with lupus.
Kwong et al. described a case of multiple autoimmune syndromes (MAS) comprising of type 1 diabetes, Hashimoto thyroiditis, and childhood-onset systemic lupus erythematosus (SLE). Although this is not a usual combination we expect to observe in polyautoimmunities, when repeated and reported, could help us integrate these new data into a more detailed understanding of disease pathogenesis and genetics, as well as possible interactions with environmental factors.
In the past decade the scientific community has drawn more attention to A20 Haploinsufficiency which is a rare autoinflammatory disorder with Behçet disease (BD) like characteristics caused by loss-of-function mutations in TNFAIP3 gene. Some of the most common symptoms of the disease are recurrent mucosal ulcers, periodic fever, musculoskeletal symptoms, skin lesions, and recurrent infections (4, 5). Aslani et al. reported two patients with A20 haploinsufficiency and HLH (6). Zanatta et al. discussed a patient with novel heterozygous mutation in TNFAIP3 who developed intestinal BD. Considering that there are not enough published cases on this topic, reports on this matter should be encouraged to reach better understanding about symptoms and complications.
Mauro et al. described the first case of Bardet–Biedl syndrome (BBS) associated with recurrent pericarditis (RP). Congenital heart diseases are the most common cardiac finding in BBS and acquired disorders like pericarditis are usually not expected in these patients. what is even more interesting, is the excellent response to treatment with anakinra in this reported patient. Contextually, Tsyklauri et al. suggested that patients with BBS have a higher prevalence of autoimmune disorders (7) but there is no published data to support the correlation between BBS and rheumatological or autoinflammatory disorders. This association is particularly compelling as it shows a new possible feature associated with BBS and suggests a plausible unknown underlying autoinflammatory mechanism in BBS.
Li et al. described a de novo missense variant in the KMT2D gene in a boy with distinctive facial features consistent with Kabuki syndrome (KS) and pulmonary hemorrhage who was diagnosed with Goodpasture's syndrome. To our knowledge, no other similar case of KS with pneumorrhagia is described in the literature. Although we cannot be certain whether Goodpasture's syndrome is part of the KS presentation or if it occurred coincidentally, this case report does expand on the phenotype of KS and the possible associated autoimmune disorders.
Lunz Macedo et al. described a patient with homozygous Factor H (FH) Deficiency who started manifesting signs of childhood-onset SLE at age 15 while his primary immunodeficiency was diagnosed at 5. It's well worth the mention that Case reports that relate autoimmune diseases like lupus to the complement system are often related to the defects in the classical complement pathway (8). However, the association between SLE and deficiencies in the components of the alternative pathway is uncommon. There is no previously published case of a patient with an initial presentation of FH deficiency with normal components of the classical pathway, who develops childhood SLE later in life. What makes this report even more noteworthy is the experimental treatment with Curcumin. Falcão DA and her team previously described a patient with FH deficiency in 2008 who showed a promising response to in vitro treatment with curcumin resulting in increased secretion of FH from the endoplasmic reticulum of the patient's fibroblasts (9). However, in vivo treatment with CURCUMIN derivatives “Theracurmin”, which was experimented with in this paper, did not result in an increase in the plasma levels of FH, C3, and FB in their patient and no change in the clinical and laboratory SLE parameters were observed.
Another interesting twist on Lupus is discussed by Li et al. which describes a case of SLE complicated with Lupus Podocytopathy (LP) and antiphospholipid syndrome (APS). We expect immune complex depositions in the mesangium, subepithelial or subendothelial regions in lupus nephropathy (10). However, Lupus podocytopathy is a non-immune complex-mediated type of lupus nephropathy. It is a newly described entity of non-immune complex-mediated lupus nephropathy and is not yet included in the updated 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification of LN (11). There are very few reported pediatric cases of LP in the literature. but the coexistence of APS and LP in the same patient with SLE has not ever been reported in children. Li et al. study reinforces the need to consider the potential co-occurrence of APS and LP.
The increasing knowledge of inflammation and immunological pathways helps with new therapeutic options for rheumatologic disorders. These advances help in further understanding disease pathophysiology and progression and its associated complications, which support the stratification of patients to treatment pathways. The introduction of biological drugs has revolutionized the management of pediatric rheumatologic diseases, primarily in juvenile idiopathic arthritis (JIA), and has led to dramatic changes in the treatment strategies.
In the observational study performed by Xu et al. the efficacy and safety of Etanercept biosimilar recombinant human TNF-α receptor II: IgG Fc fusion protein (rhTNFR-Fc) is evaluated in 60 Chinese children with JIA and entesithis related arthritis. Their study indicated that the combination of rhTNFR-Fc and methotrexate (MTX) significantly improved the symptoms and disease activity of children with JIA.
Frkovic et al. present a 16-year-old girl with psoriatic JIA and bilateral Lipoma arborescens (LA) of her knees. Her Diagnosis was confirmed when she was 13 and primarily received conservative medical treatment (MTX) and TNF inhibitor—adalimumab was added later as a step-up approach, Which resulted in an almost complete regression of LA. LA is a non-specific reactive response to chronic inflammation associated with the proliferation of synovial villi, causing intraarticular lesions. During the last decade, a growing number of reports suggest that LA has an underlying inflammatory property. However, most clinicians are doubtful about the success of anti-inflammatory therapy in these patients and recommend synovectomy as the definitive treatment (12). Even though chronic synovial inflammation is the main pathogenesis of JIA, there are only several reports of LA in JIA patients. This case report is the first case of successful use of the TNF inhibitor adalimumab for treating bilateral knee LA in a patient with psoriatic JIA.
The use of biological treatments in MIS-C (Multisystem inflammatory syndrome in children) is also a point of focus in recent literature. MIS-C is a potentially life-threatening condition triggered by SARS-COV-2 infection. Since its first description, a huge effort has been made worldwide to better understand the pathogenesis and the clinical features of this novel entity to optimize therapeutical approaches (13).
La Torre et al. discussed a rare case of pulmonary vasculitis in an MIS-C patient who was not primarily responsive to IVIG and high-dose corticosteroids. Their use of sildenafil and high-dose anakinra as rescue therapy provided amazing results. It's intriguing to think that MISC-associated pulmonary vasculitis can benefit from biological treatments but more extensive studies are required to confirm these preliminary results.
Most MIS-C cases are managed with high dose corticosteroid therapy and immunomodulatory medications (14). However, the recent revisions of ACR recommendation agree that “in mild cases, after evaluation by specialists with expertise in MIS-C, some patients may be managed with only close monitoring without immunomodulatory treatment” (15). In the case series provided by Meneghel et al. the absence of laboratory and instrumental findings of cardiac involvement was the key point for a conservative approach, although in other cohorts in which a self-limited course has been reported cardiovascular dysfunction was described.
In conclusion, all these research efforts have significantly contributed to increasing the knowledge of pathophysiological, diagnostic, and therapeutic aspects of rheumatologic disorders.
Author contributions
The concept was led by VZ provided the first draft. JW reviewed the manuscript. MB provided the first draft. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron KS, et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis. (2022) 81(7):907–21. doi: 10.1136/annrheumdis-2021-221801
2. Cetin Gedik K, Lamot L, Romano M, Demirkaya E, Piskin D, Torreggiani S, et al. The 2021 European alliance of associations for rheumatology/American college of rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: cANDLE/PRAAS, SAVI and AGS. Ann Rheum Dis. (2022) 81(5):601–13. doi: 10.1136/annrheumdis-2021-221814
3. Ashournia P, Sadeghi P, Rezaei N, Moradinejad MH, Ziaee V. Prevalence of family history of autoimmune disorders in juvenile systemic lupus erythematosus. Maedica (Bucur). (2018) 13(1):21–4. doi: 10.26574/maedica.2018.13.1.21
4. Tangye SG, Al-herz W, Bousfiha A, Cunningham-rundles C, Franco JL. The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS committee. J Clin Immunol. (2021) 41(3):666–79. doi: 10.1007/s10875-021-00980-1
5. Marzollo A, Conti F, Rossini L, Rivalta B, Leonardi L, Tretti C, et al. Neonatal manifestations of chronic granulomatous disease: MAS/HLH and necrotizing pneumonia as unusual phenotypes and review of the literature. J Clin Immunol. (2022) 42(2):299–311. doi: 10.1007/s10875-021-01159-4
6. Aslani N, Asnaashari K, Parvaneh N, Shahrooei M, Sotoudeh-Anvari M, Shahram F, et al. TNFAIP3 Mutation causing haploinsufficiency of A20 with a hemophagocytic lymphohistiocytosis phenotype: a report of two cases. Pediatr Rheumatol Online J. (2022) 20(1):78. doi: 10.1186/s12969-022-00735-1
7. Tsyklauri O, Niederlova V, Forsythe E, Prasai A, Drobek A, Kasparek P, et al. Bardet-Biedl syndrome ciliopathy is linked to altered hematopoiesis and dysregulated self-tolerance. EMBO Rep. (2021) 22(2):e50785. doi: 10.15252/embr.202050785
8. Bussone G, Mouthon L. Autoimmune manifestations in primary immune deficiencies. Autoimmun Rev. (2009) 8:332–6. doi: 10.1016/j.autrev.2008.11.004
9. Falcão DA, Reis ES, Paixão-Cavalcante D, Amano MT, Delcolli MIMV, Florido MPC, et al. Deficiency of the human complement regulatory protein factor H associated with low levels of component C9. Scand J Immunol. (2008) 68:445–55. doi: 10.1111/j.1365-3083.2008.02152.x
10. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. (2017) 12:825–35. doi: 10.2215/CJN.05780616
11. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. (2018) 93:789–96. doi: 10.1016/j.kint.2017.11.023
12. Batu ED, Sonmez HE, Kösemehmetoğlu K, Özer H, Aydingöz Ü. Lipoma arborescens associated with psoriatic arthritis in an adolescent boy: a case report and review of the literature. J Clin Rheumatol. (2020) 26:e47–49. doi: 10.1097/RHU.0000000000000833
13. Poddighe D, Ziaee V, Kasapcopur O. Editorial: cOVID-19 and hyper inflammation syndrome: different presentation and management. Front Pediatr. (2022) 10:1022701. doi: 10.3389/fped.2022.1022701
14. Sadeghi P, Gorji M, Assari R, Tahghighi F, Raeeskarami SR, Ziaee V. Methylprednisolone pulses as an initial treatment in hyperinflammatory syndrome after COVID-19 in children: evaluation of laboratory data, serial echocardiography and outcome: a case series. Intensive Care Med Exp. (2022) 10(1):56. doi: 10.1186/s40635-022-00484-1
Keywords: monogenic lupus, a20 haploinsufficiency, kabuki syndrome, factor h deficiency, bardet-Biedl syndrome, lupus podocytopathy, knee lipoma, MIS-C
Citation: Bakhtiari Koohsorkhi M, Wu J and Ziaee V (2023) Editorial: Case Reports in Pediatric Rheumatology 2022. Front. Pediatr. 11:1137843. doi: 10.3389/fped.2023.1137843
Received: 4 January 2023; Accepted: 20 January 2023;
Published: 6 February 2023.
Edited and Reviewed by: Erkan Demirkaya, Western University, Canada
© 2023 Bakhtiari Koohsorkhi, Wu and Ziaee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Vahid Ziaee WmlhZWVAdHVtcy5hYy5pcg==
Specialty Section: This article was submitted to Pediatric Rheumatology, a section of the journal Frontiers in Pediatrics